Suppr超能文献

[钙拮抗剂:基于新证据的当前及未来应用。钙通道阻滞剂降低血清尿酸水平的机制]

[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].

作者信息

Mizuta Einosuke, Hamada Toshihiro, Igawa Osamu, Shigemasa Chiaki, Hisatome Ichiro

机构信息

Division of Molecular Medicine and Therapeutics, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine, Japan.

出版信息

Clin Calcium. 2010 Jan;20(1):45-50.

Abstract

In hypertensive subjects, their serum uric acid levels tend to be higher because of decreasing urinary secretion or overproduction of uric acid. Among calcium channel blockers (CCBs) , long acting nifedipine and cilnidipine reveal serum uric acid lowering action. They decrease the production of uric acid precursor in skeletal muscles under anaerobic condition induced by hypertension or insulin resistance. Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms.

摘要

在高血压患者中,由于尿酸分泌减少或尿酸生成过多,他们的血清尿酸水平往往较高。在钙通道阻滞剂(CCB)中,长效硝苯地平和西尼地平具有降低血清尿酸的作用。它们可减少高血压或胰岛素抵抗诱导的无氧条件下骨骼肌中尿酸前体的生成。高尿酸血症不仅被认为是痛风的危险因素,也是肾脏和心血管疾病的危险因素,因此,使用对尿酸代谢无不良影响的CCB很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验